摘要
目的:分析人工肝配合胸腺肽α1在晚期肝衰竭患者免疫调节中的疗效。方法:选取2015年7月至2016年7月辽宁省锦州市中心医院收治的60例晚期肝衰竭患者,按随机数字表法分为对照组与观察组,每组30例。对照组行常规内科综合治疗,观察组在对照组基础上给予人工肝系统配合胸腺肽α1治疗。比较两组临床效果、免疫调节水平变化、肝功能及生存情况。结果:治疗后,观察组治疗总有效率及治疗6个月后生存率均高于对照组(均P<0. 05)。观察组白细胞介素(IL)-4和凝血酶原活动度(PTA)高于对照组,IL-6、IL-2受体(IL-2R)、总胆红素(TBil)、谷草转氨酶(AST)和谷丙转氨酶(ALT)水平低于对照组(均P<0. 05)。结论:人工肝配合胸腺肽α1可改善晚期肝衰竭患者的肝功能及免疫调节水平,提高生存质量,具有临床推广价值。
Objective: To investigate the clinical effect of artificial liver combined with thymosin α1 in patients with advanced liver failure who underwent immunomodulatory therapy. Methods: Sixty patients with advanced liver failure in our hospital from July 2015 to July 2016 were selected,and randomly divided into a control group and an observation group,with 30 cases in each group. The patients in the control group were treated with routine comprehensive medical treatment,and those in the observation group were treated as the control group with addition of artificial liver and thymosin α1. The clinical effects,immune regulation level,liver function and survival were compared. Results: After treatment,the total effective rate,the survival rate after 6 months and the levels of interleukin(IL)-4 and prothrombin activity(PTA)in the observation group were higher than those in the control group,while the IL-6,IL-2 receptor(IL-2 R),total bilirubin(TBil),glutamic oxaloacetic transaminase(AST)and glutamic pyruvic transaminase(ALT)levels were markedly lower(P<0. 05).Conclusion: Artificial liver combined with thymosin α1 could improve liver function,immune regulation level and quality of life in patients with advanced liver failure.
作者
宛月
Wan Yue(Infection Department,Jinzhou Central Hospital,Jinzhou 121000,China)
出处
《广西医科大学学报》
CAS
2019年第10期1623-1626,共4页
Journal of Guangxi Medical University
关键词
人工肝
胸腺肽Α1
晚期肝衰竭
免疫调节
artificial liver
thymosin α1
advanced liver failure
immune regulation
